Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Real Time Quote from BATS)

$21.40 USD

21.40
286,716

+0.19 (0.90%)

Updated Aug 4, 2025 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Meets Q2 Earnings Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 0.00% and 0.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) to Report Q2 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 42.11% and 6.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

by Indrajit Bandyopadhyay

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Zacks Equity Research

New Strong Sell Stocks for March 18th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 14.29% and 7.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Do Options Traders Know Something About Amphastar (AMPH) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Q3 Earnings Beat Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 15.39% and -8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bausch's (BHC) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bausch (BHC) reports better-than-expected results for the third quarter as the business shows recovery signs from the COVID-19 pandemic.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)

by Zacks Equity Research

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Amphastar's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Amphastar.

Zacks Equity Research

3 Reasons Why Amphastar (AMPH) Is a Great Growth Stock

by Zacks Equity Research

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue

by Zacks Equity Research

Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns

Zacks Equity Research

Why the Earnings Surprise Streak Could Continue for Amphastar (AMPH)

by Zacks Equity Research

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress

by Zacks Equity Research

Zacks.com featured highlights include: Amphastar Pharmaceuticals, ConforMIS, Kirkland Lake Gold, Cubic and Cimpress

Sanghamitra Saha headshot

What Bargain Hunting? Tap 5 Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Zacks Equity Research

Generic Drugs Industry's Prospects Uncertain Amid Coronavirus

by Zacks Equity Research

Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of 166.67% and 4.26%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?